Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 30, 2019, the board of directors of ACADIA Pharmaceuticals Inc. (the “Company”) appointed Elena Ridloff, CFA as Executive Vice President, Chief Financial Officer of the Company. Ms. Ridloff was also appointed as the Company’s principal financial officer, replacing Stephen R. Davis in that role.
Ms. Ridloff, age 39, has served as the Company’s interim Chief Financial Officer since October 2018 and as Senior Vice President, Investor Relations since April 2018. Ms. Ridloff joined the Company from Alexion Pharmaceuticals, Inc., where she served as Executive Director, Investor Relations from April 2014 to January 2016 and Vice President, Investor Relations from January 2016 to March 2018, and served as a member of Alexion’s Operating Committee. While at Alexion, Ms. Ridloff was responsible for building and leading an investor relations function. Prior to joining Alexion, Ms. Ridloff served as the Chief Executive Officer and Managing Member of BIOVISIO, an independent consulting firm providing strategic, financial and investor relations counsel to the life sciences industry, from January 2012 to April 2014. Ms. Ridloff also served as a Managing Director at Maverick Capital, a hedge fund, responsible for investments in the biotechnology, pharmaceutical, medical device and life science sectors, from July 2005 to January 2012. Ms. Ridloff earned her B.A. in History and Sociology of Science from the University of Pennsylvania, and she is a Chartered Financial Analyst.
There is no arrangement or understanding between Ms. Ridloff and any other person pursuant to which Ms. Ridloff was selected as an officer, and there are no actual or proposed transactions between the Company and Ms. Ridloff or any related person that would require disclosure under Item 404(a) of RegulationS-K.
